Free tool
FAERS Monitor: Saphnelo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761123 or its brand name (Saphnelo, Anifrolumab-Fnia). Reports on generic versions are filed under their own applications.
Reports
1,921
Serious
1,057
55% of reports
Hospitalization
332
Death reported
81
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- systemic lupus erythematosus168
- fatigue147
- arthralgia109
- headache98
- nausea88
- pain79
- rash78
- herpes zoster69
- drug ineffective67
- product dose omission issue62
- condition aggravated59
- dyspnoea55
- dizziness52
- covid-1951
- pruritus51
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 23 |
| 2022 | 191 |
| 2023 | 383 |
| 2024 | 478 |
| 2025 | 465 |
| 2026 | 381 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,238 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic lupus erythematosusSignal | 168 | 52.1 | 45.0 | 8,338 |
| herpes zosterSignal | 69 | 13.2 | 10.4 | 765 |
| covid-19Signal | 51 | 3.2 | 2.4 | 75 |
| arthralgiaSignal | 109 | 2.9 | 2.4 | 134 |
| product dose omission issueSignal | 62 | 2.3 | 1.8 | 45 |
| condition aggravatedSignal | 59 | 2.1 | 1.7 | 35 |
| fatigueSignal | 147 | 2.1 | 1.8 | 83 |
| rash | 78 | 2.0 | 1.6 | 36 |
| headache | 98 | 1.7 | 1.4 | 29 |
| pruritus | 51 | 1.5 | 1.1 | 7 |
| pain | 79 | 1.4 | 1.1 | 9 |
| nausea | 88 | 1.2 | 1.0 | 3 |
| dizziness | 52 | 1.1 | 0.9 | 1 |
| dyspnoea | 55 | 1.1 | 0.8 | 0 |
| drug ineffective | 67 | 0.6 | 0.4 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.